Drug Trial Radar · NCT05983198
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
33
Actual
Start
Nov 7, 2023
Primary completion
Mar 4, 2031
Study completion Mar 4, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn if the study drug, \[225Ac\]Ac-PSMA-R2, is safe and tolerable, and has anti-tumor activity in treated patients.
Conditions
- Prostate Cancer
Interventions
225Ac-PSMA-R2Drug
PSMA-R2 is a ligand coupled with 225Ac an alpha emitting radionuclide
68Ga-PSMA-R2Radiation
Kit for radiopharmaceutical preparation
68Ga-PSMA-11Radiation
Kit for radiopharmaceutical preparation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I Dose Escalation: Incidence and severity of DLTs during the DLT observation periodTime frame: Up to 6 weeks after the first 225Ac-PSMA-R2 dose administration
- Phase I Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) by group and frequency scheduleTime frame: From date of the first administration of 225Ac-PSMA-R2 till 30 days safety follow-up, assessed up to approximately 15 months
- Phase I Dose Escalation: TolerabilityTime frame: Up to 6 weeks after the first 225AC-PSMA-R2 dose administration
- Phase ll Dose Expansion: Overall Response Rate (ORR)Time frame: From date of the first administration of 225Ac-PSMA-R2 until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 15 months
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
Mayo Clinic Rochester
Rochester, Minnesota
Novartis Investigative Site
Darlinghurst, New South Wales, Australia
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Clermont-Ferrand, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Saint-Herblain, France
Novartis Investigative Site
Vandœuvre-lès-Nancy, France
Novartis Investigative Site
Dijon, Cote D Or, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.